Cuomo A, Boutis A, Colonese F, Nocerino D. High-rate breakthrough cancer pain and tumour characteristics - literature review and case series. Drugs Context 2023, 12.

Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, Committee EG. Management of cancer pain in adult patients: ESMO Clinical Practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–91.

Article  CAS  PubMed  Google Scholar 

Gonella S, Sperlinga R, Sciannameo V, Dimonte V, Campagna S. Characteristics of breakthrough Pain and its impact on quality of life in terminally Ill Cancer patients. Integr Cancer Ther. 2019;18:1534735419859095.

Article  PubMed  PubMed Central  Google Scholar 

Hernanz de Lucas R, Nunez Fernandez M, Gomez-Caamano A, Morera Lopez R, Fortes de la Torre I, de la Torre Tomas A, Munoz-Garzon V, Lopez Bermudo C, Manas Rueda A. Quality of life in patients with breakthrough cancer pain in radiation oncology departments in Spain: the CAVIDIOR study. Future Oncol. 2021;17(8):943–54.

Article  PubMed  Google Scholar 

Mercadante S, Maltoni M, Russo D, Adile C, Ferrera P, Rossi R, Rosati M, Casuccio A. The prevalence and characteristics of breakthrough Cancer Pain in patients receiving low doses of opioids for background Pain. Cancers (Basel). 2021;13(5):1058.

Article  PubMed  Google Scholar 

Camps Herrero C, Anton Torres A, Cruz-Hernandez JJ, Carrato A, Constenla M, Diaz-Rubio E, Feyjoo Saus M, Garcia-Foncillas J, Gascon P, Guillem V. Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. J Pain Res. 2019;12:2349–58.

Article  PubMed  PubMed Central  Google Scholar 

Perez-Hernandez C, Blasco A, Gandara A, Manas A, Rodriguez-Lopez MJ, Martinez V, Fernandez-Nistal A, Montoto C. Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study. Sci Rep. 2019;9(1):17701.

Article  PubMed  PubMed Central  Google Scholar 

Torres LM, Jimenez AJ, Cabezon A, Rodriguez MJ. Prevalence and characterization of breakthrough Pain Associated with Chronic Low Back Pain in the South of Spain: a cross-sectional, Multicenter, Observational Study. Pain Res Treat. 2018;2018:4325271.

PubMed  PubMed Central  Google Scholar 

Velazquez Rivera I, Munoz Garrido JC, Garcia Velasco P, Espana Ximenez de Enciso I, Velazquez Clavarana L. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. Adv Ther. 2014;31(1):107–17.

Article  CAS  PubMed  Google Scholar 

Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20(2):87–92.

Article  CAS  PubMed  Google Scholar 

Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, Nash DB, Pappagallo M, Payne R, Viscusi ER et al. Consensus panel recommendations for the assessment and management of breakthrough pain PART 2 MANAGEMENT. P&T 2005, 30(6):354–361.

Bossi P, Escobar Y, Pea F. Rapid-Onset opioids for management of breakthrough Cancer Pain: considerations for Daily Practice. Front Pain Res (Lausanne). 2022;3:893530.

Article  PubMed  Google Scholar 

Hashemi M, Zali A, Golmakani E, Delshad MH, Shadnoush M, Akbari ME. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Daru. 2021;29(1):51–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez AT, Viejo MN, Maradey P, Canal-Sotelo J, Mancilla PG, Rivero SG, Casillas IR, Abian MH, Bermudo CL. Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. Future Oncol. 2022;18(14):1717–31.

Article  CAS  PubMed  Google Scholar 

Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46(4):573–80.

Article  PubMed  Google Scholar 

Jandhyala R, Fullarton J. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. BMJ Support Palliat Care. 2012;2(2):156–62.

Article  PubMed  Google Scholar 

Garnock-Jones KP. Fentanyl Buccal Soluble Film: a review in breakthrough Cancer Pain. Clin Drug Investig. 2016;36(5):413–9.

Article  CAS  PubMed  Google Scholar 

ONSOLIS [package insert]. Raleigh, NC: IBSI Inc; 2016.

Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21(6):1308–14.

Article  CAS  PubMed  Google Scholar 

Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11(7):1017–23.

Article  PubMed  Google Scholar 

Finn AL, Vasisht N, Stark JG, Gever LN, Tagarro I. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. Clin Drug Investig. 2012;32(1):63–71.

Article  CAS  PubMed  Google Scholar 

Yen TY, Chiou JF, Chiang WY, Su WH, Huang MY, Hu MH, Wu SC, Lai YL. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: an open-label, multicenter study. Med (Baltim). 2018;97(30):e11593.

Article  CAS  Google Scholar 

Chiou TJ, Chao TC, Chao TY, Huang JS, Chang YF, Wang CH. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan. Cancer Rep (Hoboken). 2019;2(5):e1179.

Article  PubMed  PubMed Central  Google Scholar 

Finn AL, Hill WC, Tagarro I, Gever LN. Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis. J Pain Res. 2011;4:245–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Common Terminology Criteria for Adverse Events. (CTCAE) [https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50].

Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, Kong LR, Kurita GP, LeBlanc TW, Mercadante S, et al. Use of opioids for adults with Pain from Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023;41(4):914–30.

Article  PubMed  Google Scholar 

Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(8):977–1007.

Article  CAS  PubMed  Google Scholar 

Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157(12):2657–63.

Article  CAS  PubMed  Google Scholar 

Mishra S, Bhatnagar S, Chaudhary P, Rana SP. Breakthrough cancer pain: review of prevalence, characteristics and management. Indian J Palliat Care. 2009;15(1):14–8.

Article  PubMed  PubMed Central  Google Scholar 

Banala SR, Khattab OK, Page VD, Warneke CL, Todd KH, Yeung SJ. Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PLoS ONE. 2020;15(7):e0235461.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25(11):2805–15.

Article  CAS  PubMed  Google Scholar 

Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(4):588–601.

Article  CAS  PubMed  Google Scholar 

Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22(9):805–11.

Article  PubMed